Management of Agitation in Alzheimer's Disease

Medication Management

The American Academy of Family Physicians notes that approximately 10% of elderly patients may experience paradoxical agitation when taking lorazepam, and cognitive impairment and increased risk of falls are also potential concerns 1
The American Academy of Family Physicians recommends using lorazepam only for breakthrough agitation on an as-needed basis while optimizing the citalopram dose 1
Trazodone 25 mg with gradual titration up to 200-400 mg daily in divided doses may be considered if citalopram is ineffective, as suggested by the American Academy of Family Physicians 1
Divalproex sodium starting at 125 mg twice daily, titrating to therapeutic blood levels, may be considered if citalopram is ineffective, as suggested by the American Academy of Family Physicians 1

The American Academy of Family Physicians recommends implementing structured activities, environmental safety measures, and caregiver education to complement medication management 2
The American Journal of Psychiatry suggests establishing consistent daily routines to address potential triggers for exit-seeking behavior 3
The American Journal of Psychiatry recommends providing reassurance and redirection techniques for caregivers to address potential triggers for exit-seeking behavior 3
The BMJ suggests ensuring adequate lighting and familiar surroundings to address potential triggers for exit-seeking behavior 4

The American Journal of Psychiatry recommends assessing response to increased citalopram dose using a quantitative measure of agitation 3
The American Academy of Family Physicians notes that common SSRI side effects, such as gastrointestinal disturbances and sleep changes, should be monitored 2
The American Journal of Psychiatry suggests considering an atypical antipsychotic at low dose with careful monitoring for severe agitation with risk to self or others that doesn't respond to other interventions 3

The American Academy of Family Physicians warns that benzodiazepines like lorazepam should be avoided or minimized in elderly patients with dementia due to risks of tolerance, addiction, cognitive impairment, and paradoxical agitation 1
The American Journal of Psychiatry cautions that antipsychotics should only be used when symptoms are severe, dangerous, or cause significant distress, and after non-pharmacological interventions have been tried 3
The American Journal of Psychiatry emphasizes the importance of regular reassessment of the need for all psychotropic medications, with the goal of using the minimum effective dose for the shortest duration necessary 3

The patient's ongoing agitation toward other residents represents a clinical indication that necessitates continued mood-stabilizing therapy, with trazodone specifically indicated for control of severe agitated, repetitive, and combative behaviors in dementia patients, at dosing ranging from 25 mg daily up to 200-400 mg daily in divided doses, and buspirone useful for mild to moderate agitation, though it requires 2-4 weeks to become fully effective 5

Current medication doses should be recorded, including exact doses of trazodone and buspirone being administered, as these medications are being used as mood-stabilizing agents for control of problematic agitated and combative behaviors per established guidelines 5
If applicable, document prior attempts at GDR that resulted in increased agitation, to establish that pharmacologic management remains necessary 5

Schedule regular reassessment intervals, typically every 3-6 months, to determine if GDR becomes appropriate in the future, and monitor for medication side effects, particularly with trazodone in patients with cardiac conditions 5

Medications should be continued when clinically indicated for behavioral symptoms that pose safety risks, and the requirement for GDR does not apply when the patient has persistent symptoms requiring treatment, or dose reduction would compromise safety of the patient or others 5
The medications are being used for appropriate indications at appropriate doses, and after 9 months of treatment, reassessment should occur to determine if dose reduction is appropriate at that time, but this does not mandate reduction if symptoms persist 5